The Elusive Horizon: Biomarkers in Urothelial Carcinoma

Joshua A Linscott; Joshua J Meeks; Lars Dyrskjøt; Roger Li

doi:10.1016/j.eururo.2024.01.004

The Elusive Horizon: Biomarkers in Urothelial Carcinoma

Eur Urol. 2024 Apr;85(4):317-319. doi: 10.1016/j.eururo.2024.01.004. Epub 2024 Jan 25.

Authors

Joshua A Linscott¹, Joshua J Meeks², Lars Dyrskjøt³, Roger Li⁴

Affiliations

¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
² Departments of Urology and Biochemistry, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Jesse Brown VAMC, Chicago, IL, USA.
³ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁴ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA; Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: roger.li@moffitt.org.

PMID: 38278663
DOI: 10.1016/j.eururo.2024.01.004

Abstract

Urinary tests for circulating tumor DNA have potential for accurate discrimination of bladder cancer from other common inflammatory processes. Efforts are still needed to determine whether these tests can differentiate between cancer and field cancerization and to demonstrate clinical benefit in prospective trials.

Publication types

Editorial

MeSH terms

Biomarkers
Biomarkers, Tumor / genetics
Biomarkers, Tumor / urine
Carcinoma, Transitional Cell* / diagnosis
Carcinoma, Transitional Cell* / pathology
Circulating Tumor DNA* / genetics
Humans
Prospective Studies
Urinary Bladder Neoplasms* / diagnosis
Urinary Bladder Neoplasms* / genetics
Urinary Bladder Neoplasms* / pathology

Substances

Biomarkers
Circulating Tumor DNA
Biomarkers, Tumor

Grants and funding

I01 BX005599/BX/BLRD VA/United States